 |
 |
 |
|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Patents
Phage aggressively expands and maintains its intellectual property as these patents provide the basis for Phage’s competitive advantage in the production of protein-based pharmaceuticals. Below are tables of issued U.S. and international patents on which Phage is listed as the Assignee, as well as patent applications that are still under review by the Patent Office.
U.S. Patents
|
Assignee |
Patent |
Patent Number |
Issue Date |
Expiration |
|
Phage Biotechnology Corporation |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides (Recombinant host cells used in first generation Phage technology.) |
July 31, 2001 |
May 25, 2019 |
|
|
Phage Biotechnology Corporation |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides (First generation Phage methods for producing recombinant proteins and peptides.) |
6,794,162 |
September 21, 2004 |
May 17, 2021 |
|
Phage Biotechnology Corporation |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides (Second generation Phage technology.) |
6,773,899 |
August 10, 2004 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis (Methods of producing Cardio Vascu-Grow™.) |
November 4, 2003 |
August 15, 2021 |
|
|
Phage Biotechnology Corporation |
Kluyveromyces Strains Metabolizing Cellulosic and Hemicellulosis Materials |
7,344,876 |
March 18, 2008 |
January 16, 2024 |
|
Phage Biotechnology Corporation / Biopoly-Med. Inc. |
Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same |
10/947,513 |
September 22, 2004 |
|
|
Phage Biotechnology Corporation/ Biopoly-Med, Inc. |
Human growth hormone conjugated with biocompatible polymer |
11/187,522 |
December 20, 2005 |
|
Foreign Patents
|
Assignee |
Country |
Patent |
Patent Number |
Issue Date |
Expiration |
|
Phage Biotechnology Corporation |
Australia |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
2001284914 |
May 26, 2006 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Australia |
Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis |
2001288256 |
July 13, 2006 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Austria |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
Austria |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
E358135 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Belgium |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
Belgium |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Germany |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
Germany |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
60127561.6 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Europe |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
March 28, 2007 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
Europe |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
France |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
France |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
United Kingdom |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
United Kingdom |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Ireland |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
Ireland |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Italy |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Korea |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
10-0761486 |
September 18, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Liechtenstein |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
Netherlands |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Spain |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
|
Phage Biotechnology Corporation |
Switzerland |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1180153 |
April 13, 2005 |
May 24, 2020 |
|
Phage Biotechnology Corporation |
Switzerland |
Phage-Dependent Super-Production Of Biologically Active Protein And Peptides |
1309604 |
March 28, 2007 |
August 15, 2021 |
Home | Contact Us |
Webmaster
©2010 Phage Biotechnology Corp. All Rights Reserved